Topic: dyslipidaemia

Second generation antipsychotics (SGAs) are the first line treatment for psychosis and schizophrenia. SGAs are efficacious in reducing symptoms of these neuropsychiatric conditions; however, they are associated with metabolic side-effects that can be detrimental to a patient’s health and well-being. Patient’s taking SGAs have a three-fold increased risk of developing metabolic syndrome (MetS). MetS includes the development of type 2 diabetes, unprecedented weight gain, and dyslipidaemia. We hypothesised that SGAs disrupt mitochondrial function in the brain and periphery, and this may explain t